Earnings Call Summary | Butterfly Network(BFLY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Butterfly Network(BFLY.US) Q1 2024 Earnings Conference
The following is a summary of the Butterfly Network, Inc. (BFLY) Q1 2024 Earnings Call Transcript:
以下是蝴蝶網絡公司（BFLY）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Butterfly Network reported a Q1 2024 revenue of $17.7 million, marking a 14% increase, driven by a 22% rise in probe volume.
The company noted an adjusted EBITDA loss of $13.2 million for Q1 2024, down significantly from the $22.3 million loss last year.
The company expects a 15% to 20% revenue growth for 2024, upgrading the forecast from earlier expected low double-digit growth.
The company managed to decrease its cash requirements and is exploring non-dilutive financing options to extend the company's financial runway.
Butterfly Network報告稱，2024年第一季度收入爲1770萬美元，增長了14％，這得益於探測量增長22％。
該公司指出，2024年第一季度調整後的息稅折舊攤銷前利潤虧損爲1,320萬美元，較去年的2,230萬美元虧損大幅下降。
該公司預計，2024年的收入將增長15％至20％，從先前預期的低兩位數增長上調了預測。
該公司設法降低了現金需求，並正在探索非稀釋性融資方案，以延長公司的財務軌道。
Business Progress:
業務進展：
Butterfly Network successfully launched iQ3, a product gaining acceptance in multiple medical fields, and has a robust line of new products and services.
iQ3 global rollout is in progress, with entry into Canada and Europe planned in 2024.
Progress has been made to incorporate their technology into medical schools, including selling to five schools in Q1.
Innovation in the company continues with new features planned for the iQ+ product and a new offering - iQ+ bladder, set to launch in the U.S this quarter.
A new home care offering is in the pipeline, expected to start in 2025.
Positive feedback has been received from healthcare operators, who reported quicker, more effective diagnoses with Butterfly's technology.
Butterfly Network is making substantial investments in a semiconductor program for varied applications of ultrasound technology.
The company noted it is reducing cash burn and is confident in recapturing their momentum.
Butterfly Network成功推出了iQ3，該產品獲得了多個醫療領域的認可，並擁有一系列強大的新產品和服務。
iQ3的全球推廣正在進行中，計劃於2024年進入加拿大和歐洲。
在將其技術納入醫學院方面取得了進展，包括在第一季度向五所學校進行銷售。
該公司的創新仍在繼續，計劃爲iQ+產品提供新功能，以及定於本季度在美國推出的新產品——iQ+ balder。
一項新的家庭護理產品正在籌劃中，預計將於2025年啓動。
已經收到了來自醫療保健運營商的積極反饋，他們報告說，使用Butterfly的技術可以更快、更有效的診斷。
Butterfly Network正在對一項用於超聲技術各種應用的半導體項目進行大量投資。
該公司指出，它正在減少現金消耗，並有信心重拾勢頭。
More details: Butterfly Network IR
更多詳情： 蝴蝶網絡 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。